Heart Failure- Evidence for use of ace inhibitors & betablockers ACE Inhibiitors CONSENSUS(NEJM 87) & SOLVED (NEJM 91) included in Metaanalysis 7000pts.

Slides:



Advertisements
Similar presentations
BACK TO BASICS: PHARMACOLOGY CHAD C. CRIPE, MD Department of Anesthesiology & Critical Care Medicine Division of Cardiothoracic Anesthesiology The Children’s.
Advertisements

The Importance of Beta-Blockers in Patients with Heart Failure: A Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT) Analysis.
Heart Failure- II prognosis And Management
Effects of Multidisciplinary Care of Heart Failure Patients at High Risk for Hospital Admission S. Scott Sutton, Pharm.D. Associate Clinical Professor.
La stratificazione del rischio aritmico oltre la frazione di eiezione Milano 17 Aprile 2009 Prof. Luigi Padeletti Heart Failure & Co.
McMurray JJV, Young JB, Dunlap ME, Granger CB, Hainer J, Michelson EL et al on behalf of the CHARM investigators Relationship of dose of background angiotensin-converting.
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
Effects of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomized trial -- the Losartan Heart Failure Survival.
Losartan Heart Failure Survival Study ELITE II Losartan Heart Failure Survival Study ELITE II A Multicenter, Double-Blind, Randomized, Parallel, Captopril-Controlled.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
Purpose To determine whether metoprolol controlled/extended release
CHARM Program: 3 Component trials comparing candesartan with placebo.
Carvedilol Or Metoprolol European Trial Presented at European Heart Failure Meeting 2003 COMET Trial.
MIRACL, Val-HeFT, Cheney Clinical Trial Commentary Dr Eric Topol Chairman and Professor, Department of Cardiology Director of the Joseph J Jacobs Center.
Management of Acute Myocardial Infarction Minimal Acceptable vs Optimal Care Hussien H. Rizk, MD Cairo University.
1 Heart Failure William Chavey, MD, MS Associate Professor Department of Family Medicine University of Michigan.
Efficacy and safety of angiotensin receptor blockers: a meta-analysis of randomized trials Elgendy IY et al. Am J Hypertens. 2014; doi:10,1093/ajh/hpu209.
HEART FAILURE MANAGEMENT -RAAS BLOCKERS FAZIL BISHARA SR- CARDIOLOGY
ICD FOR PRIMARY PREVENTION EVIDENCE REVIEW
Dr. Jon Salisbury Visiting Physician Services A Member of VNA Health Group No Disclosures May 14, :40PM – 2:00PM ©AAHCM.
May 23rd, 2012 Hot topics from the Heart Failure Congress in Belgrade.
Heart Failure and Qof Quiz Justin Walker October 2010.
Journey of Beta blockers
Modern Management of heart Failure Dr Amanda Varnava Consultant Cardiologist Watford & St Mary’s Hospitals.
Update on  -Blockers In the Management of Heart Failure.
Systolic CHF Therapy Rogers Kyle, MD 10/2/12. Learning Objectives Review the staging and evaluation of patients with systolic heart failure Review the.
Heart Failure Ben Starnes MD FACC Interventional Cardiology
Appendix: Clinical Guidelines VBWG. I Intervention is useful and effective III Intervention is not useful or effective and may be harmful A Data derived.
CHARM-Preserved: Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity - Preserved Purpose To determine whether the angiotensin.
Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: is there an influence of beta-blocker dose? Systolic.
Clinical implications. Burden of coronary disease 56 millions deaths worldwide in millions deaths worldwide in % due to CV disease (~ 16.
Hypertension In elderly population. JNC VII BP Classification SBP mmHgDBP mmHg Normal
S ystolic H eart failure treatment with the I f inhibitor ivabradine T rial Main results Swedberg K, et al. Lancet. 2010;376(9744):
Heart Failure Pharmacology
RALES: Randomized Aldactone Evaluation Study Purpose To determine whether the aldosterone antagonist spironolactone reduces mortality in patients with.
The Renin-Angiotensin System
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.
COMET - Background, Rationale and Design Pharmacological Differences Within the  Blocker Class Agents currently evaluated for heart failure 
Heart failure: The national burden AHA. Heart disease and stroke statistics–2005 update. Koelling TM et al. Am Heart J. 2004;147:74-8. VBWG Affects 1 million.
IRIS Post-hoc Analysis Background IRIS compared the safety and efficacy of early ICD implantation with medical treatment alone in 898 patients at high.
ALLHAT Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial JAMA 2002;288:
CIBIS II Cardiac Insufficiency Bisoprolol Study
Binu George , Heather Bury Critical care Journal Club May 2014
HYPERTENSION RECOMMENDATIONS FOR FOLLOW UP BASED ON INITIAL BP READING
Polypill x Aspirin Project Groups 3 and 4
COMET: Carvedilol Or Metoprolol European Trial Purpose To compare the effects of carvedilol (a β 1 -, β 2 - and α 1 -receptor blocker) and short-acting.
Heart rate in heart failure: Heart rate in heart failure: risk marker or risk factor? A subanalysis of the SHIFT trial on behalf of the Investigators M.
An ICD for every CRT patient ?
ELITE - II Study Design  60 yrs; NYHA II - IV; EF  40 % ACEI naive or  7 days in 3 months prior to entry Standard Rx ( ± Dig / Diuretics ), ß - blocker.
Relationship of background ACEI dose to benefits of candesartan in the CHARM-Added trial.
Candesartan in Heart Failure Presented at European Society of Cardiology 2003 CHARM Trial.
SS-1 Candesartan Support Slides. SS-2 Baseline Beta-Blocker Charm Added β-blocker Of patients on β-blockers Mean daily dose of β-blocker CandesartanPlacebo.
COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,
Heart Failure J. Lynn Davis, M.D. Cardiologist CHI St. Vincent Heart Clinic Arkansas April 25, 2015.
HEART FAILURE. Excellent Care 1. Diagnosis 2. ACE-I and B blocker 3. Aldosterone antagonist 4. Exercise 5. Statin and aspirin if CVD 6. Digoxin with AF.
© Continuing Medical Implementation ® …...bridging the care gap Geriovascular Prevention Optimizing Prevention of Cardiovascular Disease in the Elderly.
Date of download: 7/5/2016 Copyright © The American College of Cardiology. All rights reserved. From: Early Aldosterone Blockade in Acute Myocardial Infarction:
Date of download: 7/10/2016 From: β-Blockers in Congestive Heart Failure: A Bayesian Meta-Analysis Ann Intern Med. 2001;134(7): doi: /
Date of download: 9/19/2016 Copyright © The American College of Cardiology. All rights reserved. From: What resting heart rate should one aim for when.
Total Occlusion Study of Canada (TOSCA-2) Trial
Clinical Trial Commentary
JOURNAL REVIEW HEART FAILURE MANAGEMENT – BETA BLOCKERS
Section III: Neurohormonal strategies in heart failure
Outcome Relative risk with beta blockers 95% CI Stroke –1.30
CIBIS II: Cardiac Insufficiency Bisoprolol Study II
The Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) Study was a double-blind, randomized, placebo-controlled study.
ß-blocker therapy for heart failure at the turn of the millennium
Marrick L. Kukin, MD  Mayo Clinic Proceedings 
Presentation transcript:

Heart Failure- Evidence for use of ace inhibitors & betablockers ACE Inhibiitors CONSENSUS(NEJM 87) & SOLVED (NEJM 91) included in Metaanalysis 7000pts Decreased risk of mortality Most benefit with EF<25% Trend towards reduced MI, sudden cardiac death & CVA Doses Rx in primary care were lower than recommended ALTAS ’99higher doses of lisinopril did better with SE’s not increased on higher doses mg /day vs % lower death(p=0.128 & 24%less hospitalisations(p=0.002)

ARB(angiotensin 2 antagonist) ELITE (evaluation of losartan in elderly) Lancet 97 ELITE 1 – less morbitity & mortality than captopril Death & hospitalisation for heart failure 9.4% (losa.) Vs 13.2% (capt) NNT 26 Elite 2 (lancet 2000) Insufficient datat to recommend ARB as 1 st line Rx Stuides on going about using these in conjunction with Ace inhibitors

Beta blockers Originally CI Cardiac Insufficiency Bisoprolol Study 2 (Fundadam Clin Pharm 97)relative risk reduction 35 % in NYHA 3-5 Carvedilol Heart Failure study (NEJM 96)- mortality rate over an average 6.5/ Vs 7.8% in control MERIT-HF Lancet 99 Metoprolol (CR/XL randomised intervention Relative risk reduction 94%, improved survival, functional class & well being when added to standard Rx

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com. Inc. All rights reserved.